{"title": "Design, synthesis, antitubercular and antiviral properties of new spirocyclic indole derivatives", "body": "Tuberculosis (TB) is a highly infectious disease caused by the bacillus Mycobacterium tuberculosis. For the past 5 years, it has been the leading cause of mortality from a single infectious disease, ranking above HIV/AIDS [1]. Major problems associated with the currently available TB treatment include long treatment duration, inadequate compliance, concurrent HIV infection, and increasing incidence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis [2\u20135]. This emergence of difficult to treat strains necessitates the discovery and development of novel antitubercular drugs. After this domain has been inactive for several decades, two new drugs became available, i.e., the mitochondrial ATP synthase inhibitor bedaquiline and mycolic acid biosynthesis inhibitor delamanid, which received accelerated approval for the treatment of MDR tuberculosis in 2012 and 2014, respectively [6]. Besides, diverse novel drug candidates are in preclinical or clinical development [6\u20138].\n\nIndole-2-carboxamides incorporating an alicyclic system (Fig. 1a) have been extensively studied by different research groups [9\u201314]. This type of compounds was found to be highly active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis by acting on the MmpL3 transporter protein. In previous investigations, we have identified the indole-spirothiazolidinone system (Fig. 1b) as a promising scaffold against the Mycobacterium tuberculosis H37Rv strain [15, 16]. Some of these analogues exhibited in vitro antitubercular activity with GI (growth inhibition) values of 91\u201395% at a MIC (minimum inhibitory concentration) value of 6.25 \u00b5g/cm3. Recently, we reported on the synthesis of novel 5-fluoro-3-phenyl-1H-indole derivatives containing a 4-thiazolidinone nucleus (instead of spirothiazolidinone system) [17]. Two molecules (Fig. 1c) displayed notable antitubercular activity at concentrations tenfold lower than those that produced cytotoxicity in mammalian cell lines.\n\nFurthermore, several spirothiazolidinone compounds synthesized in our laboratory were found to be efficient inhibitors of membrane fusion mediated by influenza virus hemagglutinin (HA) [18\u201320]. As demonstrated in Fig. 1d, these compounds have a similar backbone structure, consisting of an aromatic/polycyclic ring linked to a non-aromatic spiro system via an amide bridge. Some analogues displayed low micromolar activity against the influenza A/H3N2 subtype with a favorable selectivity index.\n\nBased on these insights and our objective to optimize the antimicrobial activity of indolyl thiazolidinones and spirothiazolidinones, we here report the chemical synthesis, structural characterization and in vitro antitubercular, antiviral, antibacterial, and antifungal evaluation of new 5-chloro-3-phenyl-N-(2,7,8,9-substituted/nonsubstituted-3-oxo-1-thia-4-azaspiro[4.4]nonan/[4.5]decan-4-yl)-1H-indole-2-carboxamides 4a\u20134i, 5a\u20135h (Fig. 1e).\n\nThe synthetic pathways for the preparation of the spirothiazolidinones 4a\u20134i and 5a\u20135h are illustrated in Scheme 1. Thus, the diazonium salt, formed by the reaction of 4-chloroaniline with NaNO2 and HCl, was reacted with ethyl 2-benzyl-3-oxobutanoate to obtain compound 1 [21] according to the Japp\u2013Klingemann reaction. The Fischer indole synthesis was carried out in acidic medium to cyclize 1 into ethyl 5-chloro-3-phenyl-1H-indole-2-carboxylate 2 [22]. Subsequent exposure of 2 to an excess of hydrazine hydrate afforded compound 3 [23]. The target spirocyclic compounds 4a\u20134i, 5a\u20135h were synthesized by treatment of the key intermediate 3 with appropriate cyclic ketones and mercapto acids in a one-pot reaction [15].\n\nThe structures of the new compounds were characterized by IR, 1H NMR, 13C NMR (proton decoupled, APT, and DEPT), electrospray ionization mass spectrometry (ESI-MS), and combustion analysis. The IR spectra of 4a\u20134i and 5a\u20135h exhibited the ring and the exocyclic C=O bands in the 1692\u20131713 cm\u22121 and 1651\u20131670 cm\u22121, respectively. The shifts observed in the amide bands when compared to that of 3 (1636 cm\u22121) and the presence of additional lactam bands provided definite proof for the aimed cyclization. Observation of NH signals assigned to the indole NH (\u03b4 = 12.11\u201312.18 ppm) and amide NH (9.97\u20130.21 ppm) together with the absence of the NH2 resonance of the intermediate hydrazide 3 in the 1H NMR spectra of 4 and 5, provided further evidence for the formation of new adducts. The S\u2013CH2 (4a\u20134i) and S\u2013CH (5a\u20135h) protons of the newly formed spiroalkane residue resonated at about 3.50-3.65 and 3.87-3.93 ppm, respectively. The S\u2013CH2 protons of 4a\u20134i appeared as singlets except for the methylene hydrogens of compound 4g which were observed as separate doublets with large coupling constants (J = 16.1 Hz) due to the geminal coupling resulting from the chiral centers of the spirothiazolidinone ring. The 1H NMR spectra of 5a\u20135h displayed the thiazolidinone S\u2013CH protons as quartets or broad/distorted singlets and doublets. Assignment of the indole protons was achieved on the basis of the values and coupling constants reported for the 2,3,5-trisubstituted indole ring [15, 16, 24, 25]. The carbon resonances were assigned by chemical shifts and comparison with previously reported 13C NMR data for compounds having a similar backbone structure [15, 19, 26]. CH3, CH2, CH, and C signals were assigned by APT and DEPT experiments. Observation of the typical C5 (\u03b4 = 70.59\u201376.40 ppm) and C=O (167.64\u2013170.57 ppm) resonances of the spirothiazolidinone structure in the 13C NMR spectra of 4 and 5, verified the formation of the expected spiro ring system.\n\nDeprotonated [M \u2212 H]\u2212 or protonated [M + H]+ ions observed in the ESI-MS confirmed the molecular weight of the compounds. Additional [(M \u2212 H) + 2]\u2212 or [(M + H) + 2]+ isotope peaks approximately one-third the intensity of the molecular ion peak resulting from the 37Cl isotope further confirmed the new structures.\n\nThe antitubercular activity of compounds 4a\u20134i and 5a\u20135h was tested in vitro against M. tuberculosis H37Rv ATCC 27294 using the microdilution method. The lowest concentration of compound that inhibited 100% of mycobacterial growth in the culture was defined as the MIC. Rifampicin was used as the reference drug. Compounds were assayed using twofold dilutions starting at 1000 \u00b5M. As shown in Table 1, compounds 4 h and 5h, bearing a phenyl substituent at position 8 of the spiro ring, exhibited the highest anti-TB activity at concentrations of 3.9 and 7.8 \u00b5M, respectively. Most of the compounds in series 4 (4b, 4c, 4d, 4f, and 4i) displayed some activity on mycobacteria with MIC values of 16 and 31 \u00b5M.\n\nLooking at the chemical structures of the active compounds, it can be observed that the presence of a methyl group at position 2 of the spirocyclic system (series 5) led to a significant reduction in antitubercular activity. Introduction of a bulky aromatic substituent (C6H5) at position 8 of the ring, as in 4h and 5h, enhanced the antitubercular activity.\n\nCompounds 4a\u20134i and 5a\u20135h were evaluated against a variety of DNA and RNA viruses in cell culture, namely: herpes simplex virus type-1 (HSV-1) and type-2 (HSV-2), an acyclovir-resistant thymidine kinase-deficient (TK\u2212) mutant of HSV-1, vaccinia virus, human adenovirus-2, human coronavirus, vesicular stomatitis virus, Coxsackie B4 virus, respiratory syncytial virus, parainfluenza-3 virus, reovirus, Sindbis virus, Punta Toro virus, yellow fever virus, and influenza A and influenza B virus. The cytopathic effect reduction assays revealed that compounds 4b, 4c, 5b, and 5d were moderately active against Punta Toro virus, yellow fever virus or Sindbis virus in Vero cells (Table 2). The antiviral EC50 values were in the range of 1.9\u201312 \u00b5M and the selectivity index (SI: ratio of cytotoxic to antivirally effective concentration) was above 10 in some cases (see values between brackets in Table 2). The most potent effect was seen with compound 5d that is methylated at positions 2 and 8 of the spirothiazolidinone system. Of note, no antiviral activity was obtained for the analogues carrying a spiro-fused cyclopentane ring instead of cyclohexane (i.e., 4a and 5a) or a bulkier group than methyl on the cyclohexane residue. Introduction of a methyl group at position 2 of the ring system (e.g., compare compounds 4b and 5b) seemed to have a slightly positive effect on antiviral activity.\n\nThe test compounds did not exhibit activity against any of the other DNA- or RNA-viruses tested. Nevertheless, this broad antiviral testing allowed to determine the compounds\u2019 cytotoxic activity in different mammalian cell lines (Table 3). In general, the compounds endowed with antiviral activity (4b, 4c, 5b, and 5d) tended to be less cytotoxic than the inactive derivatives.\n\nThe broad antibacterial and antifungal activity of compounds 4a\u20134i and 5a\u20135 h was further assessed using Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 4352, Proteus mirabilis ATCC 14153, Staphylococcus aureus ATCC 29213, Staphylococcus epidermidis ATCC 12228, Enterococcus faecalis ATCC 29212, Candida albicans ATCC 10231, Candida parapsilosis ATCC 22019, and Candida tropicalis ATCC 750. The compounds were assayed using twofold dilutions from 2500 to 156 \u00b5M. Neither of the test compounds produced antimicrobial activity below this concentration range.\n\nIn the search for effective antimicrobial agents, we achieved the synthesis of novel spirothiazolidinone derivatives 4a\u20134i 5a\u20135h with the 5-chloro-3-phenyl-1H-indole scaffold. Structures of the new compounds were characterized and confirmed by spectrometric methods (IR, 1H NMR, 13C NMR, and ESI-MS) and elemental analysis. Compounds 4a\u20134i and 5a\u20135h were evaluated for in vitro antitubercular, antiviral, antibacterial, and antifungal activity against various viral, bacterial, and fungal strains. Compounds 4h and 5h, bearing a bulky phenyl group at position 8 of the spiro ring, displayed appreciable anti-TB activity against M. tuberculosis H37Rv ATCC 27294 with MIC values of 3.9 and 7.8 \u00b5M, respectively. Compounds 4b, 4c, 5b, and 5d exhibited inhibitory effect on the replication of Punta Toro virus, yellow fever virus or Sindbis virus in Vero cells. The antiviral EC50 values were in the range of 1.9\u201312 \u00b5M and the selectivity index (SI: ratio of cytotoxic to antivirally effective concentration) was above 10 in some cases. The most potent effect was seen with compound 5d that is methylated at positions 2 and 8 of the spirothiazolidinone system. Neither of the indole-spirothiazolidinone compounds showed activity against any of the bacterial or fungal strains tested, at concentrations below 2500\u2013156 \u00b5M.\n\nTo a solution of 4-chloroaniline (0.02 mol) in 10 cm3 ethanol, 10 cm3 water, and 6 cm3 conc. HCl, 30 cm3 aqueous NaNO2 solution (7%) was added dropwise at 0 \u00b0C with stirring. The resulting solution of diazonium salt was poured into a cooled (0 \u00b0C) mixture of ethyl 2-benzyl-3-oxobutanoate (0.02 mol), 10 cm3 ethanol, 10 cm3 water, and 5.4 g KOH while stirring. The resulting mixture was refrigerated overnight. The red oily solid residue thus obtained was separated, washed with water, and used without further purification. Yield: 72.4%; m.p.: 90\u201393 \u00b0C (Ref. [21] 87\u201393 \u00b0C).\n\nA solution of 1 (0.02 mol) in 20 cm3 conc. HCl was heated under reflux on a water bath (70\u201380 \u00b0C) for 4 h. The crude product was filtered off, washed with water until tested neutral to litmus and used without further purification. Yield: 67.8%; m.p.: 160\u2013162 \u00b0C (Ref. [22] 158\u2013160 \u00b0C).\n\nA mixture of 2 (0.02 mol), 20 cm3 ethanol, and 8 cm3 H2NNH2\u00b7H2O (98%) was heated under reflux on a water bath (70\u201380 \u00b0C) for 6 h. The resulting brown solid was filtered off and recrystallized from ethanol. Yield: 53.7%; m.p.: 227\u2013230 \u00b0C (Ref. [23] 234\u2013236 \u00b0C).\n\nWhite crystals; yield: 87.7%; m.p.: 297\u2013300 \u00b0C; Rf= 0.46 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3277 (N\u2013H), 1709, 1651 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 1.58\u20131.69 (4H, m, CH2-sp.), 1.72\u20131.74 (2H, m, CH2-sp.), 1.94 (2H, s*, CH2-sp.), 3.65 (2H, s, S\u2013CH2-sp.), 7.29 (1H, dd, J = 8.5, 2.0 Hz, H6-ind.), 7.37 (1H, tt, J = 7.3, 1.5 Hz, 3-C6H5(H4)-ind.), 7.45 (2H, t, J = 7.3 Hz, 3-C6H5(H3,H5)-ind.), 7.51\u20137.54 (4H, m, H4, H7, 3-C6H5(H2,H6)-ind.), 10.10 (1H, s, CONH), 12.13 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 22.40, 29.05, 37.91 (CH2-sp.), 76.40 (C5-sp.), 114.62, 114.67 (CH-ar.), 118.64 (C-ar.), 119.32, 119.41 (CH-ar.), 124.69 (CH-ar.), 125.50 (C-ar.), 127.75 (CH-ar.), 127.81 (C-ar.), 128.03 (C-ar.), 128.79 (CH-ar.), 130.44 (CH-ar.), 133.27 (C-ar.), 134.65 (C-ar.), 162.08 (CO\u2013NH), 167.87 (CO-sp.) ppm; MS (ESI-): m/z (%) = 424.5 ([M \u2212 H]\u2212, 100), 426.3 ([(M \u2212 H) + 2]\u2212, 36.5).\n\nWhite crystals; yield: 76.9%; m.p.: 229\u2013232 \u00b0C; Rf= 0.48 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3279 (N\u2013H), 1709, 1651 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 1.01\u20131.11 (2H, m, CH2-sp.), 1.35\u20131.42 (2H, m, CH2-sp.), 1.56 (1H, d*, J = 13.2 Hz, CH2-sp.), 1.64\u20131.72 (5H, m, CH2-sp.), 3.58 (2H, s, S\u2013CH2-sp.), 7.30 (1H, dd, J = 8.8, 2.4 Hz, H6-ind.), 7.37 (1H, tt, J = 7.3, 1.5 Hz, 3-C6H5(H4)-ind.), 7.46 (2H, t, J = 7.6 Hz, 3-C6H5(H3,H5)-ind.), 7.51\u20137.56 (4H, m, H4, H7, 3-C6H5(H2,H6)-ind.), 10.09 (1H, s, CONH), 12.14 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 23.33, 24.31, 28.29, 37.10 (CH2-sp.), 72.63 (C5-sp.), 114.56, 114.64 (CH-ar.), 118.50 (C-ar.), 119.31, 119.39 (CH-ar.), 124.54, 124.66 (CH-ar.), 125.47 (C-ar.), 127.41 (CH-ar.), 127.82 (C-ar.), 128.23 (C-ar.), 128.90 (CH-ar.), 130.51 (CH-ar.), 133.38 (C-ar.), 134.62 (C-ar.), 162.14 (CO\u2013NH), 167.73 (CO-sp.) ppm.\n\nWhite powder; yield: 83.4%; m.p.: 268\u2013270 \u00b0C; Rf= 0.52 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3231 (N\u2013H), 1711, 1651 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 0.76\u20130.85 (1H, m, CH/CH2-sp.), 0.87 (3H, d, J = 6.4 Hz, 7-CH3-sp.), 1.24\u20131.70 (8H, m, CH/CH2-sp.), 3.58 (2H, s, S\u2013CH2-sp.), 7.29 (1H, dd, J = 8.8, 2.0 Hz, H6-ind.), 7.37 (1H, tt, J = 7.3, 1.5 Hz, 3-C6H5(H4)-ind.), 7.45 (2H, t, J = 7.3 Hz, 3-C6H5(H3,H5)-ind.), 7.49 (1H, d, J = 2.0 Hz, H4-ind.), 7.52-7.54 (3H, m, H7, 3-C6H5(H2,H6)-ind.), 10.06 (1H, s, CONH), 12.14 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 22.42 (7-CH3-sp.), 22.88, 28.36 (CH2-sp.), 29.97 (C7-sp.), 32.98, 36.54, 45.20 (CH2-sp.), 72.59 (C5-sp.), 114.56, 114.63 (CH-ar.), 118.50 (C-ar.), 119.28, 119.37 (CH-ar.), 124.54 (CH-ar.), 125.45 (C-ar.), 127.42 (CH-ar.), 127.85 (C-ar.), 128.25 (C-ar.), 128.91 (CH-ar.), 130.51 (CH-ar.), 133.43 (C-ar.), 134.62 (C-ar.), 162.18 (CO\u2013NH), 167.66 (CO-sp.) ppm.\n\nWhite powder; yield: 91.2%; m.p.: 292\u2013293 \u00b0C; Rf= 0.51 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3285 (N\u2013H), 1709, 1651 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 0.89, 0.95 (3H, 2d, J = 6.4 Hz, 8-CH3-sp.), 1.08\u20131.32 (3H, m, CH/CH2-sp.), 1.64\u20131.75 (6H, m, CH/CH2-sp.), 3.57, 3.58 (2H, 2 s, S\u2013CH2-sp.), 7.29, 7.30 (1H, 2dd, J = 8.5, 2.4 Hz, H6-ind.), 7.36 (1H, tt, J = 8.0, 1.5 Hz, 3-C6H5(H4)-ind.), 7.46 (2H, t, J = 7.8 Hz, 3-C6H5(H3,H5)-ind.), 7.51-7.55 (4H, m, H4, H7, 3-C6H5(H2,H6)-ind.), 10.05, 10.06 (1H, 2 s, CONH), 12.11, 12.12 (1H, 2 s, NH) ppm; 13C NMR (proton decoupled and DEPT, DMSO-d6, 75 MHz): \u03b4 = 22.23 (8-CH3-sp.), 28.19 (CH2-sp.), 30.70 (C8-sp.), 31.73, 36.76 (CH2-sp.), 72.39 (C5-sp.), 114.50 (CH-ar.), 118.43 (C-ar.), 119.25 (CH-ar.), 124.52 (CH-ar.), 125.38 (C-ar.), 127.26 (CH-ar.), 127.73 (C-ar.), 128.06 (C-ar.), 128.76 (CH-ar.), 130.37 (CH-ar.), 133.26 (C-ar.), 134.53 (C-ar.), 162.00 (CO\u2013NH), 167.69 (CO-sp.) ppm; MS (ESI-): m/z (%) = 452.6 ([M \u2212 H]\u2212, 100), 454.4 ([(M \u2212 H) + 2]\u2212, 34.3).\n\nWhite flakes; yield: 88.2%; m.p.: 236\u2013237 \u00b0C; Rf= 0.53 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3283 (N\u2013H), 1713, 1651 (C=OC=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 0.89 (3H, t, J = 7.3 Hz, 8-CH2CH3-sp.), 1.04\u20131.35 (5H, m, CH/CH2-sp., 8-CH2CH3-sp.), 1.62\u20131.96 (6H, m, CH/CH2-sp.), 3.58, 3.59 (2H, 2 s, S\u2013CH2-sp.), 7.30 (1H, dd, J = 8.8, 2.0 Hz, H6-ind.), 7.36 (1H, tt, J = 7.3, 1.5 Hz, 3-C6H5(H4)-ind.), 7.45 (2H, t, J = 7.3 Hz, 3-C6H5(H3,H5)-ind.), 7.51-7.56 (4H, m, H4, H7, 3-C6H5(H2,H6)-ind.), 10.09, 10.10 (1H, 2 s, CONH), 12.13 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 11.94 (8-CH2CH3-sp.), 28.29, 28.35, 29.22, 29.41, 36.84 (CH2-sp., 8-CH2CH3-sp.), 37.45 (C8-sp.), 72.75 (C5-sp.), 114.55, 114.63 (CH-ar.), 118.48 (C-ar.), 119.29, 119.38 (CH-ar.), 124.64 (CH-ar.), 125.47 (C-ar.), 127.40 (CH-ar.), 127.81 (C-ar.), 128.24 (C-ar.), 128.87 (CH-ar.), 130.48 (CH-ar.), 133.38 (C-ar.), 134.60 (C-ar.), 162.11 (CO\u2013NH), 167.78 (CO-sp.) ppm; MS (ESI\u2212): m/z (%) = 466.8 ([M-H]\u2212, 100), 468.5 ([(M-H) + 2]\u2212, 30.9).\n\nBeige powder; yield: 75.7%; m.p.: 233-236 \u00b0C; Rf = 0.55 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3291, 3217 (N\u2013H), 1707, 1661 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 0.88 (3H, t, J = 7.3 Hz, 8-CH2CH2CH3-sp.), 1.05\u20131.34 (7H, m, CH/CH2-sp., 8-CH2CH2CH3-sp.), 1.60\u20131.82 (6H, m, CH/CH2-sp.), 3.58 (2H, s, S\u2013CH2-sp.), 7.29 (1H, dd, J = 8.8, 2.0 Hz, H6-ind.), 7.35 (1H, tt, J = 7.3, 1.5 Hz, 3-C6H5(H4)-ind.), 7.45 (2H, t, J = 7.8 Hz, 3-C6H5(H3,H5)-ind.), 7.51 (1H, d, J = 2.0 Hz, H4-ind.), 7.53\u20137.56 (3H, m, H7, 3-C6H5(H2,H6)-ind.), 10.10 (1H, s, CONH), 12.13 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 14.58 (8-CH2CH2CH3-sp.), 19.99, 28.30, 28.36, 29.77 (CH2-sp., 8-CH2CH2CH3-sp.), 35.25 (C8-sp.), 36.85, 38.76 (CH2-sp., 8-CH2CH2CH3-sp.), 72.74 (C5-sp.), 114.55, 114.61 (CH-ar.), 118.47 (C-ar.), 119.30, 119.38 (CH-ar.), 124.54 (CH-ar.), 125.47 (C-ar.), 127.30 (CH-ar.), 127.67 (C-ar.), 128.28 (C-ar.), 128.84 (CH-ar.), 130.51 (CH-ar.), 133.42 (C-ar.), 134.61 (C-ar.), 162.12 (CO\u2013NH), 167.77 (CO-sp.) ppm.\n\nWhite crystals; yield: 85.1%; m.p.: 264-266.5 \u00b0C; Rf = 0.56 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3277, 3219 (N\u2013H), 1705, 1695, 1665 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 0.76 (1H, t, J = 12.7 Hz, CH/CH2-sp.), 0.90 (6H, s*, 7-(CH3)2-sp.), 1.04 (3H, s*, 9-CH3-sp.), 1.20-1.34 (2H, m, CH/CH2-sp.), 1.58-1.84 (4H, m, CH/CH2-sp.), 3.50 (1H, d, J = 16.1 Hz, S\u2013CH2-sp.), 3.61 (1H, d, J = 16.1 Hz, S\u2013CH2-sp.), 7.29 (1H, dd, J = 8.6, 2.0 Hz, H6-ind.), 7.37 (1H, t*, J = 7.3 Hz, 3-C6H5(H4)-ind.), 7.44\u20137.48 (3H, m, H4, 3-C6H5(H3,H5)-ind.), 7.51\u20137.54 (3H, m, H7, 3-C6H5(H2,H6)-ind.), 9.97 (1H, s, CONH), 12.13 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 22.24, 25.97, 27.64 (7-(CH3)2, 9-CH3-sp.), 28.50, 32.24 (CH2-sp.), 34.09 (C9-sp.), 45.23, 46.80, 47.31 (CH2-sp., C7-sp.), 71.87 (C5-sp.), 114.56, 114.64 (CH-ar.), 118.50 (C-ar.), 119.28, 119.38 (CH-ar.), 124.58 (CH-ar.), 125.45 (C-ar.), 127.44 (CH-ar.), 127.96 (C-ar.), 128.18 (C-ar.), 128.99 (CH-ar.), 130.54 (CH-ar.), 133.47 (C-ar.), 134.62 (C-ar.), 162.40 (CO\u2013NH), 167.64 (CO-sp.) ppm.\n\nBeige powder; yield: 72.8%; m.p.: 285\u2013287 \u00b0C; Rf = 0.58 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3277, 3237 (N\u2013H), 1707, 1663 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 1.60\u20131.91 (8H, m, CH2-sp.), 2.47\u20132.49 (1H, m, CH-sp.), 3.64 (2H, s, S\u2013CH2-sp.), 7.21 (1H, tt*, J = 7.3, 1.5 Hz, 8-C6H5(H4)-sp.), 7.25 (2H, d*, J = 7.3 Hz, 8-C6H5-sp.), 7.29\u20137.34 (3H, m, H6-ind., 8-C6H5-sp.), 7.41 (1H, tt*, J = 7.8, 1.5 Hz, 3-C6H5(H4)-ind.), 7.50\u20137.61 (6H, m, H4, H7, 3-C6H5(H2,H3,H5,H6)-ind.), 10.18 (1H, s, CONH), 12.17 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 28.38, 30.92, 37.12 (CH2-sp.), 41.95 (C8-sp.), 72.10 (C5-sp.), 114.57, 114.64 (CH-ar.), 118.60 (C-ar.), 119.34, 119.42 (CH-ar.), 124.62 (CH-ar.), 125.51 (C-ar.), 126.98 (8-ar.(CH)-sp.), 127.09 (CH-ar.), 127.73 (8-ar.(CH)-sp.), 127.88 (C-ar.), 128.28 (C-ar.), 128.95 (CH-ar.), 130.57 (CH-ar.), 133.45 (C-ar.), 134.63 (C-ar.), 146.26 (8-ar.(C)-sp.), 162.18 (CO\u2013NH), 167.84 (CO-sp.) ppm.\n\nWhite crystals; yield: 79.3%; m.p.: 230-232 \u00b0C; Rf= 0.57 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3285 (N\u2013H), 1702, 1662 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 0.84 (9H, s, 8-C(CH3)3-sp.), 0.90-0.96 (1H, m, CH/CH2-sp.), 1.12\u20131.22 (2H, m, CH/CH2-sp.), 1.64-1.72 (6H, m, CH/CH2-sp.), 3.58 (2H, s, S\u2013CH2-sp.), 7.30 (1H, dd, J = 8.8, 2.0 Hz, H6-ind.), 7.36 (1H, tt, J = 7.3, 1.5 Hz, 3-C6H5(H4)-ind.), 7.45 (2H, t, J = 7.3 Hz, 3-C6H5(H3,H5)-ind.), 7.50 (1H, d, J = 2.0 Hz, H4-ind.), 7.52-7.56 (3H, m, H7, 3-C6H5(H2,H6)-ind.), 10.13 (1H, s, CONH), 12.14 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 24.14 (CH2-sp.), 27.80 (8-C(CH3)3-sp.), 28.28 (CH2-sp.), 32.39 (8-C(CH3)3-sp.), 37.11 (CH2-sp.), 45.96 (C8-sp.), 72.57 (C5-sp.), 114.60 (CH-ar.), 118.42 (C-ar.), 119.27, 119.35 (CH-ar.), 124.64 (CH-ar.), 125.45 (C-ar.), 127.40 (CH-ar.), 127.84 (C-ar.), 128.38 (C-ar.), 128.90 (CH-ar.), 130.51 (CH-ar.), 133.44 (C-ar.), 134.58 (C-ar.), 162.13 (CO\u2013NH), 167.79 (CO-sp.) ppm; MS (ESI-): m/z (%) = 494.5 ([M-H]\u2212, 100), 496.3 ([(M-H) + 2]\u2212, 37.6).\n\nBeige powder; yield: 85.4%; m.p.: 270\u2013272 \u00b0C; Rf= 0.60 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3283 (N\u2013H), 1709, 1651 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 1.42 (3H, d, J = 6.8 Hz, 2-CH3-sp.), 1.59-1.77 (6H, m, CH2-sp.), 1.91-2.08 (2H, m, CH2-sp.), 3.93 (1H, q, J = 6.8 Hz, S\u2013CH-sp.), 7.29 (1H, dd, J = 8.8, 2.0 Hz, H6-ind.), 7.36 (1H, tt, J = 7.8, 1.5 Hz, 3-C6H5(H4)-ind.), 7.44 (2H, t, J = 7.8 Hz, 3-C6H5(H3,H5)-ind.), 7.50-7.55 (4H, m, H4, H7, 3-C6H5(H2,H6)-ind.), 10.14 (1H, s, CONH), 12.13 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 19.81 (2-CH3-sp.), 22.47 (CH2-sp.), 37.93, 38.06 (C2-sp.), 38.25, 38.37 (CH2-sp.), 74.96 (C5-sp.), 114.60, 114.66 (CH-ar.), 118.64 (C-ar.), 119.33, 119.41 (CH-ar.), 124.63, 124.74 (CH-ar.), 125.49 (C-ar.), 127.48 (CH-ar.), 127.84 (C-ar.), 128.02 (C-ar.), 128.81 (CH-ar.), 130.48 (CH-ar.), 133.27 (C-ar.), 134.65 (C-ar.), 162.05 (CO\u2013NH), 170.57 (CO-sp.) ppm.\n\nWhite crystals; yield: 90.7%; m.p.: 245\u2013248 \u00b0C; Rf = 0.62 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3285 (N\u2013H), 1711, 1651 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 1.02\u20131.11 (2H, m, CH2-sp.), 1.31\u20131.38 (2H, m, CH2-sp.), 1.41 (3H, d, J = 6.8 Hz, 2-CH3-sp.), 1.56 (1H, d, J = 12.7 Hz, CH2-sp.), 1.62\u20131.75 (5H, m, CH2-sp.), 3.93 (1H, q, J = 6.4 Hz, S\u2013CH-sp.), 7.30 (1H, dd, J = 8.8, 2.0 Hz, H6-ind.), 7.37 (1H, t, J = 7.3 Hz, 3-C6H5(H4)-ind.), 7.47 (2H, t, J = 7.3 Hz, 3-C6H5(H3,H5)-ind.), 7.50-7.55 (4H, m, H4, H7, 3-C6H5(H2,H6)-ind.), 10.12 (1H, s, CONH), 12.14 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 20.01 (2-CH3-sp.), 23.59, 24.31 (CH2-sp.), 37.12 (C2-sp.), 38.02 (CH2-sp.), 71.29 (C5-sp.), 114.56, 114.63 (CH-ar.), 118.50 (C-ar.), 119.31, 119.39 (CH-ar.), 124.63 (CH-ar.), 125.46 (C-ar.), 127.42 (CH-ar.), 127.84 (C-ar.), 128.23 (C-ar.), 128.90 (CH-ar.), 130.54 (CH-ar.), 133.37 (C-ar.), 134.62 (C-ar.), 162.11 (CO\u2013NH), 170.36 (CO-sp.) ppm.\n\nWhite crystals; yield: 86.0%; m.p.: 262\u2013264 \u00b0C; Rf= 0.65 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3235 (N\u2013H), 1694, 1661 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 0.75\u20130.80 (1H, m, CH/CH2-sp.), 0.87 (3H, d, J = 6.0 Hz, 7-CH3-sp.), 1.23\u20131.68 (8H, m, CH/CH2-sp.), 1.41 (3H, d, J = 6.3 Hz, 2-CH3-sp.), 3.88 (1H, s*, S\u2013CH-sp.), 7.29 (1H, dd, J = 8.6, 2.0 Hz, H6-ind.), 7.37 (1H, tt, J = 7.3, 1.5 Hz, 3-C6H5(H4)-ind.), 7.45\u20137.49 (3H, m, H4, 3-C6H5(H3,H5)-ind.), 7.52-7.54 (3H, m, H7, 3-C6H5(H2,H6)-ind.), 10.07 (1H, s, CONH), 12.12 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 20.01, 20.03 (2-CH3-sp.), 22.38, 22.48 (7-CH3-sp.), 22.72, 23.12 (CH2-sp.), 29.86, 30.25 (C7-sp.), 32.98, 36.66 (CH2-sp.), 37.27, 37.38 (C2-sp.), 37.71, 45.41, 46.10 (CH2-sp.), 71.22, 71.26 (C5-sp.), 114.55, 114.63 (CH-ar.), 118.52 (C-ar.), 119.29, 119.39 (CH-ar.), 124.56, 124.65 (CH-ar.), 125.45 (C-ar.), 127.42 (CH-ar.), 127.88 (C-ar.), 128.25 (C-ar.), 128.90 (CH-ar.), 130.55 (CH-ar.), 133.43 (C-ar.), 134.62 (C-ar.), 162.14 (CO\u2013NH), 170.30 (CO-sp.) ppm; MS (ESI-): m/z (%) = 466.7 ([M-H]\u2212, 100), 468.5 ([(M-H) + 2]\u2212, 33.4).\n\nWhite crystals; yield: 95.1%; m.p.: 223-225.5 \u00b0C; Rf= 0.65 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3337, 3262 (N\u2013H), 1694, 1670 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 0.89, 0.96 (3H, 2d, J = 6.4 Hz, 8-CH3-sp.), 1.03-1.36 (3H, m, CH/CH2-sp.), 1.41 (3H, d, J = 6.8 Hz, 2-CH3-sp.), 1.50-1.74 (6H, m, CH/CH2-sp.), 3.87 (1H, q*, J = 6.8 Hz, S\u2013CH-sp.), 7.30, 7.31 (1H, 2dd, J = 8.8, 2.0 Hz, H6-ind.), 7.37 (1H, tt, J = 7.3, 1.5 Hz, 3-C6H5(H4)-ind.), 7.46 (2H, t, J = 7.3 Hz, 3-C6H5(H3,H5)-ind.), 7.50 (1H, d, J = 2.0 Hz, H4-ind.), 7.52\u20137.58 (3H, m, H7, 3-C6H5(H2,H6)-ind.), 10.10 (1H, s, CONH), 12.13 (1H, s, NH) ppm; 13C NMR (proton decoupled and DEPT, DMSO-d6, 75 MHz): \u03b4 = 20.24 (2-CH3-sp.), 22.25 (8-CH3-sp.), 30.71 (C8-sp.), 31.60, 32.02, 36.91 (CH2-sp.), 37.10 (C2-sp.), 37.78 (CH2-sp.), 71.05 (C5-sp.), 114.50 (CH-ar.), 118.43 (C-ar.), 119.26 (CH-ar.), 124.52 (CH-ar.), 125.38 (C-ar.), 127.27 (CH-ar.), 127.75 (C-ar.), 128.08 (C-ar.), 128.76 (CH-ar.), 130.41 (CH-ar.), 133.27 (C-ar.), 134.53 (C-ar.), 161.98 (CO\u2013NH), 170.33 (CO-sp.) ppm.\n\nWhite needles; yield: 87.2%; m.p.: 198\u2013200 \u00b0C; Rf= 0.64 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3383 (N\u2013H), 1711, 1653 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 0.89 (3H, t, J = 7.3 Hz, 8-CH2CH3-sp.), 1.02\u20131.24 (5H, m, CH/CH2-sp., 8-CH2CH3-sp.), 1.41 (3H, d, J = 6.8 Hz, 2-CH3-sp.), 1.62-1.88 (6H, m, CH/CH2-sp.), 3.87 (1H, q*, J = 6.3 Hz, S\u2013CH-sp.), 7.30 (1H, dd, J = 8.8, 2.0 Hz, H6-ind.), 7.37 (1H, tt, J = 7.8, 1.5 Hz, 3-C6H5(H4)-ind.), 7.46 (2H, t, J = 7.8 Hz, 3-C6H5(H3,H5)-ind.), 7.51 (1H, d, J = 2.0 Hz, H4-ind.), 7.52\u20137.56 (3H, m, H7, 3-C6H5(H2,H6)-ind.), 10.13 (1H, s, CONH), 12.13 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 11.92 (8-CH2CH3-sp.), 20.35 (2-CH3-sp.), 29.23, 29.67, 36.98 (CH2-sp., 8-CH2CH3-sp.), 37.14, 37.27 (C2-sp.), 37.42 (C8-sp.), 37.85 (CH2-sp., 8-CH2CH3-sp.), 71.42, 71.71 (C5-sp.), 114.55, 114.61 (CH-ar.), 118.50 (C-ar.), 119.32, 119.39 (CH-ar.), 124.56, 124.64 (CH-ar.), 125.46 (C-ar.), 127.39 (CH-ar.), 127.85 (C-ar.), 128.24 (C-ar.), 128.88 (CH-ar.), 130.51 (CH-ar.), 133.39 (C-ar.), 134.60 (C-ar.), 162.07 (CO\u2013NH), 170.41 (CO-sp.) ppm.\n\nBeige crystals; yield: 89.1%; m.p.: 194\u2013197 \u00b0C; Rf= 0.67 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3287, 3184 (N\u2013H), 1713, 1692, 1653 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 0.88 (3H, t, J = 7.3 Hz, 8-CH2CH2CH3-sp.), 1.00\u20131.34 (7H, m, CH/CH2-sp., 8-CH2CH2CH3-sp.), 1.42 (3H, d, J = 6.8 Hz, 2-CH3-sp.), 1.60\u20131.84 (6H, m, CH/CH2-sp.), 3.89 (1H, d*, J = 5.8 Hz, S\u2013CH-sp.), 7.30 (1H, dd, J = 8.8, 2.0 Hz, H6-ind.), 7.36 (1H, tt, J = 7.3, 1.5 Hz, 3-C6H5(H4)-ind.), 7.45 (2H, t, J = 7.3 Hz, 3-C6H5(H3,H5)-ind.), 7.50 (1H, d, J = 2.0 Hz, H4-ind.), 7.52-7.56 (3H, m, H7, 3-C6H5(H2,H6)-ind.), 10.13 (1H, s, CONH), 12.13 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 14.57 (8-CH2CH2CH3-sp.), 20.00 (CH2-sp., 8-CH2CH2CH3-sp.), 20.31 (2-CH3-sp.), 29.62, 30.05 (CH2-sp., 8-CH2CH2CH3-sp.), 35.26 (C8-sp.), 37.00 (CH2-sp., 8-CH2CH2CH3-sp.), 37.16, 37.29 (C2-sp.), 37.86, 38.79 (CH2-sp., 8-CH2CH2CH3-sp.), 71.39, 71.75 (C5-sp.), 114.53, 114.60 (CH-ar.), 118.50 (C-ar.), 119.32, 119.39 (CH-ar.), 124.55, 124.64 (CH-ar.), 125.47, 125.52 (C-ar.), 127.36 (CH-ar.), 127.66 (C-ar.), 128.27 (C-ar.), 128.84 (CH-ar.), 130.55 (CH-ar.), 133.32, 133.43 (C-ar.), 134.61, 134.66 (C-ar.), 162.08 (CO\u2013NH), 170.37, 170.41 (CO-sp.) ppm; MS (ESI-): m/z (%) = 494.7 ([M \u2212 H]\u2212, 100), 496.4 ([(M \u2212 H) + 2]\u2212, 34.2).\n\nWhite crystals; yield: 75.5%; m.p.: 266-268 \u00b0C; Rf= 0.68 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3287 (N\u2013H), 1705, 1655 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 0.76 (1H, t, J = 12.7 Hz, CH/CH2-sp.), 0.90 (6H, s*, 7-(CH3)2-sp.), 1.03 (3H, d, J = 6.4 Hz, 9\u2013CH3-sp.), 1.24\u20131.42 (2H, m, CH/CH2-sp.), 1.38 (3H, d, J = 6.8 Hz, 2-CH3-sp.), 1.62\u20131.80 (4H, m, CH/CH2-sp.), 3.87 (1H, s*, S\u2013CH-sp.), 7.29, 7.30 (1H, 2dd, J = 8.8, 2.0 Hz, H6-ind.), 7.38 (1H, t*, J = 7.3 Hz, 3-C6H5(H4)-ind.), 7.45\u20137.48 (3H, m, H4, 3-C6H5(H3,H5)-ind.), 7.50\u20137.54 (3H, m, H7, 3-C6H5(H2,H6)-ind.), 10.02 (1H, s, CONH), 12.13, 12.17 (1H, 2 s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 20.05 (2-CH3-sp.), 22.23, 25.68, 26.21, 27.69 (7-(CH3)2, 9-CH3-sp.), 32.27 (CH2-sp.), 36.84, 36.96 (C9-sp.), 37.46, 37.57 (C2-sp.), 45.22, 46.80, 47.29 (CH2-sp., C7-sp.), 70.59 (C5-sp.), 114.56, 114.63 (CH-ar.), 118.52 (C-ar.), 119.29, 119.38 (CH-ar.), 124.58, 124.67 (CH-ar.), 125.44 (C-ar.), 127.44 (CH-ar.), 127.98 (C-ar.), 128.18, 128.24 (C-ar.), 128.97 (CH-ar.), 130.54 (CH-ar.), 133.46, 133.48 (C-ar.), 134.61 (C-ar.), 162.44 (CO\u2013NH), 170.24 (CO-sp.) ppm; MS (ESI +): m/z (%) = 497.1 ([M + H]+, 31.2), 426.3 ([(M + H) + 2]+, 10.7).\n\nBeige powder; yield: 82.3%; m.p.: 213\u2013215 \u00b0C; Rf= 0.69 (EtOAc/CHCl3 1:1); IR (KBr): \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\bar{\\nu }$$\\end{document}\u03bd\u00af = 3289 (N\u2013H), 1705, 1663 (C=O) cm\u22121; 1H NMR (DMSO-d6, 500 MHz): \u03b4 = 1.45 (3H, d, J = 6.8 Hz, 2-CH3-sp.), 1.58-2.00 (8H, m, CH2-sp.), 2.45-2.51 (2H, m, CH-sp., DMSO-d6), 3.92 (1H, d*, J = 5.6 Hz, S\u2013CH-sp.), 7.20 (1H, tt*, J = 7.3, 1.5 Hz, 8-C6H5(H4)-sp.), 7.25 (2H, d*, J = 6.8 Hz, 8-C6H5-sp.), 7.30-7.34 (3H, m, H6-ind., 8-C6H5-sp.), 7.42 (1H, tt*, J = 7.3, 1.5 Hz, 3-C6H5(H4)-ind.), 7.51-7.61 (6H, m, H4, H7, 3-C6H5(H2,H3,H5,H6)-ind.), 10.21 (1H, s, CONH), 12.18 (1H, s, NH) ppm; 13C NMR (APT, DMSO-d6, 125 MHz): \u03b4 = 20.03 (2-CH3-sp.), 30.76, 31.24 (CH2-sp.), 37.38 (C2-sp.), 38.10 (CH2-sp.), 41.95 (C8-sp.), 70.78 (C5-sp.), 114.57, 114.63 (CH-ar.), 118.61 (C-ar.), 119.34, 119.43 (CH-ar.), 124.59, 124.69 (CH-ar.), 125.49 (C-ar.), 126.97 (8-ar.(CH)-sp.), 127.08 (CH-ar.), 127.43 (8-ar.(CH)-sp.), 127.91 (C-ar.), 128.27 (C-ar.), 128.95 (CH-ar.), 130.63 (CH-ar.), 133.45 (C-ar.), 134.63 (C-ar.), 146.28 (8-ar.(C)-sp.), 162.14 (CO\u2013NH), 170.47 (CO-sp.) ppm; MS (ESI-): m/z (%) = 528.8 ([M-H]\u2212, 100), 530.8 ([(M-H) + 2]\u2212, 33.8).\n\nThe microdilution method was performed according to a standard protocol from the Clinical and Laboratory Standard Institute (CLSI) [27, 28]. The resazurin microtitre assay (REMA) has been developed as a colorimetric and standard method for drug susceptibility testing. The minimum inhibitory concentrations (MICs) were determined according to color changes at the end of incubation [29\u201331]. The strain used, i.e., Mycobacterium tuberculosis H37Rv ATCC 27294 is susceptible to all common antimycobacterial drugs.\n\nMiddlebrook 7H9 broth medium (Becton and Dickinson, USA) was used and the medium was adjusted to pH 7.0 at 25 \u00b0C. Each bottle was controlled for sterility before it was used. Resazurin purchased from Sigma-Aldrich (St Louis, USA) was dissolved in sterile distilled water to a final concentration of 0.02% and sterilized by filtration, then stored at 4 \u00b0C until use. Rifampicin purchased from Becton\u2013Dickinson (BD, USA) was dissolved in sterile distilled water to a final concentration of 1 \u03bcg/cm3 (critical concentration). The synthesized compounds were dissolved in 100% dimethyl sulfoxide according to CLSI methods [27, 28]. Stock solutions were obtained by 40-fold dilution in DMSO followed by sterile filtration. From here, working stocks at 4000 \u03bcM were obtained by diluting 1/10 in MB7H9 medium. The final concentrations were 1000 \u03bcM to 0.49 \u03bcM for the synthesized compounds. For rifampicin, the critical concentration (1 \u03bcg/cm3) was used [27, 28].\n\nInoculum suspensions of mycobacteria were prepared according to the CLSI guidelines as described previously. The isolates were subcultured on L\u00f6wenstein Jensen medium and incubated at 37 \u00b0C for 20\u201325 days. A few colonies from freshly grown M. tuberculosis were suspended in Middlebrook 7H9 broth medium to obtain 1.0 McFarland turbidity, then diluted ten times with the same medium.\n\nThe broth microdilution test was performed in sterile 96-well U-shaped microdilution plates (LP Italiano SPA, Milano, Italy). Rows A\u2013F contained 100 mm3 of the compound dilutions, whereas rows G (positive control) and H (negative control) contained 100 mm3 medium. One hundred mm3 of the corresponding inoculum was added to all wells except for row H. The microplates were incubated at 35 \u00b0C for about 7\u201310 days, when mycobacterial growth was clearly visible as a white sediment in the positive control. Microbial growth was confirmed by Ehrlich\u2013Ziehl\u2013Neelsen acid-fast stain. Resazurin solution (30 mm3) was added to each well and the plates were incubated for one additional day. At that time, the first purple colored well in which no growth was visible, was defined as the compounds\u2019 MIC value (Table 1).\n\nStock solutions of the test and reference compounds were prepared in 100% DMSO at 5\u201325 mM. During incubation with the cells, the highest test concentration was 100 \u00b5M (or 250 \u00b5M for ribavirin). The antiviral reference compounds were: ganciclovir, brivudin, zanamivir, amantadine, ribavirin, dextran sulfate-10,000, and mycophenolic acid. Antiviral evaluation was carried out with a broad panel of viruses using cytopathic effect (CPE) reduction assays. Human influenza A (H1N1 and H3N2) and B viruses were examined on Madin\u2013Darby canine kidney (MDCK) cells. Respiratory syncytial virus, vesicular stomatitis virus and Coxsackie B4 virus were evaluated on human cervix carcinoma HeLa cells. African Green Monkey Vero cells were used for parainfluenza-3 virus, reovirus-1, Sindbis virus, Coxsackie B4 virus, Punta Toro virus and yellow fever virus. Human embryonic lung (HEL) fibroblast cells were infected with herpes simplex virus types 1 and 2, vaccinia virus, human adenovirus-2, and human coronavirus 229E.\n\nSemiconfluent cell cultures in 96-well plates were infected with virus at a multiplicity of infection of 100 CCID50 (50% cell culture infective dose) per well. Together with the virus, fourfold dilutions of the test or reference compounds were added. The plates were incubated at 37 \u00b0C (or 35 \u00b0C for influenza- and coronavirus) until far advanced CPE was visible, i.e., during 3\u20136 days or 10 days in the case of adenovirus-2. Then, microscopy was performed to score the CPE and calculate the 50% antivirally effective concentration (EC50). Microscopy was also done to assess cytotoxicity, expressed as the compound concentration causing minimal changes in cell morphology (minimal cytotoxic concentration; MCC).\n\nAntimicrobial activity against Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 4352, Proteus mirabilis ATCC 14153, Staphylococcus aureus ATCC 29213, Staphylococcus epidermidis ATCC 12228, Enterococcus faecalis ATCC 29212, Candida albicans ATCC 10231, Candida parapsilosis ATCC 22019, and Candida tropicalis ATCC 750 was determined by the microbroth dilutions technique using CLSI recommendations [32, 33]. Serial twofold dilutions ranging from 2500 \u00b5M to 1.22 \u00b5M were prepared in the test medium, i.e., Mueller\u2013Hinton broth for bacteria and RPMI-1640 medium for yeast strains. The inoculum was prepared using a 4\u20136 h broth culture of each bacteria type and 24 h culture of yeast strains adjusted to a turbidity equivalent to 0.5 McFarland standard, diluted in broth media to give a final concentration in the test tray of 5 \u00d7 105 cfu/cm3 for bacteria and 5 \u00d7 103 cfu/cm3 for yeast. The trays were covered and placed into plastic bags to prevent evaporation. The bacteria trays were incubated at 35 \u00b0C for 18\u201320 h while the yeast-containing trays were incubated at 35 \u00b0C for 46\u201350 h. The MIC was defined as the lowest concentration of compound giving complete inhibition of visible growth. Amikacin and fluconazole were used as reference antibiotics for bacteria and yeast, respectively; their MIC values were within the accuracy range of the CLSI guidelines [34].\n"}